Rivastigmine Tartrate

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced China Medical System Holdings Limited (CMS) New Drug Application (NDA) for ZUNVEYL has been accepted by the National Medical Products Administration of China (NMPA) for review for the treatment of mild-to-moderate Alzheimer’s dementia. “We are pleased to announce the NMPA acceptance of the ZUNVEYL New Drug Application, marking a significant milestone in our mission to bring innovative treatments to patients in need," said Michael McFadden, Chief Executive Officer of Alpha Cognition. "This acceptance reflects the strength of our partnership with CMS and the dedication of our team. We look forward to working closely with our partner throughout this important review process as we move one step closer to potentially delivering this important therapy to the Asia market." Alpha Cognition will rely on successful regulatory and commercial expertise of CMS in the Chinese market and will benefit financially from advances in China and other Asia territories. The Company is eligible to receive regulatory, sales milestones, and royalties should ZUNVEYL be approved for marketing in China and other Asia territories. According to the epidemiological study results published in the Lancet Public Health, there are about 7.93 million patients with mild-to-moderate Alzheimer dementia in China. With the intensifying aging trend, the number of patients and the consequent disease burden will further increase in the future. The Company anticipates additional progress across other countries with regulatory advancement and ZUNVEYL commercial approvals. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ALPHA-1062 (benzgalantamine) formulated as a delayed release oral tablet (ZUNVEYL®), is FDA approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as a sublingual formulation for cognitive Impairment with mTBI. INDICATION AND USAGE ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredients in ZUNVEYL. Serious skin reactions have occurred. WARNINGS AND PRECAUTIONS Serious Skin Reactions: Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported in patients receiving galantamine (the active metabolite of ZUNVEYL tablets). If signs or symptoms suggest a serious skin reaction, use of this drug should not be resumed, and alternative therapy should be considered. Anesthesia: See Drug Interactions Section Cardiovascular Conditions: Cholinesterase inhibitors, including ZUNVEYL, have vagotonic effects on the sinoatrial and atrioventricular nodes, leading to bradycardia and AV block. Bradycardia and all types of heart block have been reported in patients taking cholinesterase inhibitors, both with and without known underlying cardiac conduction abnormalities. Therefore, all patients should be considered at risk for adverse effects on cardiac conduction. Patients treated with galantamine up to 24 mg/day using the recommended dosing schedule showed a dose-related increase in risk of syncope. Gastrointestinal Conditions: Cholinesterase inhibitors, including ZUNVEYL, may increase gastric acid secretion. Patients should be monitored closely for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical studies of galantamine have shown no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding. Galantamine has been shown to produce nausea, vomiting, diarrhea, anorexia, and weight loss. Monitor the patient's weight during therapy with ZUNVEYL. Genitourinary Conditions: Although this was not observed in clinical trials with galantamine, cholinesterase inhibitors, including ZUNVEYL, may cause bladder outflow obstruction. Neurological Conditions: Cholinesterase inhibitors are believed to have some potential to cause generalized convulsions. Seizure activity may also be a manifestation of Alzheimer's disease. Patients with Alzheimer's disease should be monitored closely for seizures while taking ZUNVEYL. Pulmonary Conditions: Cholinesterase inhibitors, including ZUNVEYL, should be prescribed with care to patients with a history of severe asthma or obstructive pulmonary disease. Monitor for respiratory adverse reactions. ADVERSE REACTIONS The most common adverse reactions with galantamine tablets (≥5%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite. DRUG INTERACTIONS Use with Anticholinergics: Galantamine has the potential to interfere with the activity of anticholinergic medications. Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol. USE IN SPECIFIC POPULATIONS Pregnancy: Based on animal data may cause fetal harm. Hepatic Impairment: In patients with moderate hepatic impairment, a decrease in clearance of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with severe hepatic impairment is not recommended. Renal Impairment: In patients with a creatinine clearance of 9 to 59 mL/min, an increase in exposure of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with creatinine clearance less than 9 mL/min is not recommended. These are not all of the possible side effects of ZUNVEYL. You can report side effects to the FDA. Visit www.fda.gov/MedWatch or call 1‑800‑FDA‑1088. Please click here for Full Prescribing Information. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the potential benefits of the licensing agreement for the development and commercialization of ZUNVEYL in Asia (excluding Japan), Australia and New Zealand, the Company’s timing and planned activities to launch ZUNVEYL in the U.S. and China, the timing for the Company’s planned corporate update call, the potential timing for the availability of ZUNVEYL in the U.S. and China, the potential future developments of ZUNVEYL in China, the potential market size for ZUNVEYL in China, the Company’s business strategy for the launch of ZUNVEYL in China, the market size and demand for ZUNVEYL in China, the Company’s potential growth opportunities in China, the timing and results of the Company’s milestone payments for China, the Company’s regulatory submissions in China, and the potential regulatory approval and commercialization of the Company’s products in China. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at www.sedar.com and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Form S-1/A registration statement as filed with the SEC on November 6, 2024 and available at www.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.

WEEKLY REPORT07/252025产业简报本期导读本周要闻产业洞察产业研报近期活动最新课程本 周 要 闻SHINE CONSULTANT行业快讯News Flashes沃森生物(300142.SZ)：与玉溪运营公司签署战略合作框架协议沃森生物(300142.SZ)公布，公司于2025年7月22日与玉溪国有资本运营有限公司(简称“玉溪运营公司”)签署了《云南沃森生物技术股份有限公司与玉溪国有资本运营有限公司的战略合作框架协议》。基于公司持续发展及业务扩张需求，以及双方拥有的业务、技术、市场、资本、产业等优势资源，双方拟通过资源整合，实现优势互补，助力产业发展升级，经双方友好协商，签署本协议。本协议约定的双方合作期限暂定为三年，经双方同意后可展期。双方拟围绕疫苗及生物制品产业领域建立长期、稳定、全面、深入的战略合作关系，通过充分调动双方优质产业资源，推动公司在创新疫苗及合成生物制造行业的产业升级和业务扩张发展。双方将充分发挥各自优势，在产业资源、产业布局、产业落地等各方面深化协同。（格隆汇）华森制药：新增委托生产药品健儿消食口服液华森制药(002907.SZ)公告称，公司近日收到重庆市药品监督管理局颁发的《药品生产许可证》，本次变更主要涉及新增委托生产（仅限持有人变更）。受托方为河南灵佑药业股份有限公司，委托品种为健儿消食口服液（国药准字Z41021020），生产场地为郑州市新郑新村镇万庄路合剂（含口服液）、酒剂、溶液剂车间：合剂（含口服液）生产线，委托有效期至2025年11月09日。该变更有利于公司优化产业结构，增加消化领域的销售品种，有助于丰富公司产品管线及开拓零售市场，以满足市场需求。短期内对公司业绩无重大影响。（财联社）人福医药：利斯的明透皮贴剂获药品注册证书人福医药7月22日公告，控股子公司宜昌人福近日收到国家药品监督管理局核准签发的利斯的明透皮贴剂的《药品注册证书》。利斯的明透皮贴剂获批适应症为：用于治疗轻、中度阿尔茨海默病的症状。宜昌人福于2023年3月向国家药品监督管理局提交利斯的明透皮贴剂的上市许可申请并获得受理，截至目前该项目累计研发投入约为人民币1900万元。（界面新闻）艾方生物获数千万元首轮融资，兴湘资本投资7月23日消息，湖南艾方生物科技有限公司（以下简称“艾方生物”）成功获得数千万元首轮股权融资，投资方为兴湘资本。此轮股权融资将为艾方生物在产品研发、市场拓展以及团队建设等方面注入强大动力。湖南艾方生物科技有限公司成立于2020年，位于长沙湘江新区，是一家专注于肿瘤病理诊断试剂集研发、生产、销售为一体的国家高新技术企业、专精特新中小企业、长沙市智能制造试点企业。拥有超 7000 余平方米的研发、生产实验室，20 项授权专利，并有多个发明专利正在申请中，主要项目为mIHC多重荧光染色&数据AI高阶分析整体解决方案、临床病理诊断免疫组化。（投资界）华仁药业：盐酸甲氧氯普胺原料药上市申请获批华仁药业(300110)7月21日晚间公告，公司全资子公司安徽恒星制药近日收到国家药监局核准签发的“盐酸甲氧氯普胺”《化学原料药上市申请批准通知书》。盐酸甲氧氯普胺适用于预防术后恶心和呕吐；恶心和呕吐的对症治疗，包括偏头痛发作引起的恶心和呕吐；预防放射治疗引起的恶心和呕吐。另外，全资子公司青岛华仁医疗用品有限公司近日收到山东省药监局核准签发的“一次性使用无菌无芯杆溶药注射器”的《医疗器械注册证》。（证券时报）人事变动Personnel Changes圣诺医药-B(02257.HK)：于常海博士辞任独立非执行董事圣诺医药-B(02257.HK)公告，董事会已接获于常海博士的辞任函，由于于博士欲投放更多时间于其他事务，故辞任独立非执行董事、董事会提名委员会主席、董事会审核委员会成员、董事会薪酬委员会成员以及董事会调查委员会成员，自2025年10月18日起生效。（格隆汇）领航医药生物科技(00399.HK)委任伍鸣为首席执行官领航医药生物科技(00399.HK)宣布，现任公司执行董事伍鸣将由2025年7月17日起获委任为公司首席执行官。（格隆汇）产 业 洞 察SHINE CONSULTANT01全球首批！拜耳first-in-class新药获批上市点击阅读全文产 业 研 报SHINE CONSULTANT012023年中国企业医疗健康管理白皮书022022年中国康复医疗行业研究报告03合成生物学产业链及应用场景042023年家用医疗智能器械商业路径发展报告05医疗产业链中数字化场景发展现况及挑战062022年药品市场生命周期研究之GLP-1RA篇07中国医疗器械行业数据报告(2025版)点击阅读全文 活 动 预 告SHINE CONSULTANT2025(第九届)亚太生物医药合作峰会，8月28日-29日 · 上海最 新 课 程SHINE CONSULTANT生物医药行业研究与投资逻辑（点击查看）全面汇总：医药全行业研究分析框架与投资逻辑详解（点击查看）联系我们Sunny Sun 孙女士T:021 6095 0241M:189 6294 0579（微信同号）E:sunny.sun@shine-consultant.com会议咨询媒体合作商务合作欢迎详询洽谈！SHINE CONSULTANT上海士研管理咨询有限公司成立于2005年，致力于为组织领导者提供沟通交流与专家智库平台。通过二十年沉淀与积累，覆盖了金融与投资、交通与运输、消费与文旅、医药与医疗、能源与资源、高科与电信、公用与政府等产业领域，服务着全球500强和万余家领导型企业，汇聚了百万余名机构决策者，并与千余家产业权威机构建立了战略伙伴关系。士研咨询秉承专业立身的理念发展队伍，现拥有百余名专业的资深人员，核心管理团队都具有十五年以上的专业经验。